Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Business Wire•29/09/2026•07:00 ET
0
Key Highlights
- ➤Zai Lab (ZLAB) will present first global zoci data at ESMO Congress 2026
- ➤Phase 1b/1c trial evaluates zoci plus atezolizumab with or without carboplatin
- ➤Poster presentation targets first-line treatment of extensive-stage small cell lung cancer
- ➤Investor call and webcast scheduled October 23 at 8:00 a.m. ET
- ➤Zoci is being evaluated as a potential backbone ADC in first-line combinations
Expert Statements
Rafael G. Amado, President, Head of Global Research and Development at Zai Lab
“We look forward to sharing results from this trial evaluating zoci as first-line therapy for small cell lung cancer, one of the most aggressive and lethal solid tumors”
Rafael G. Amado, President, Head of Global Research and Development at Zai Lab
“We continue to be encouraged by zoci’s potential best-in-class safety profile, coupled with compelling systemic and intracranial efficacy that support zoci monotherapy as a potential new standard of care in previously treated ES-SCLC, as well as a backbone ADC in first-line combination regimens, including those that reduce the burden of chemotherapy.”
Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
* Poster presentation at ESMO Congress 2026 will highlight findings from trial of zoci in combination with atezolizumab with and without carboplatin
Get started
Create a free account to read the full story.